Arcutis Biotherapeutics (ARQT) Q3 2024 earnings summary

Executive summary

• Q3 2024 net product revenue reached $44.8 million, up 452% year-over-year and 45% quarter-over-quarter, driven by strong ZORYVE franchise growth, new indication launches, and robust prescription demand.

• ZORYVE now covers psoriasis, seborrheic dermatitis, and atopic dermatitis, with strong physician adoption, market share gains, and over 485,000 total prescriptions since launch.

• Expanded Medicaid coverage now spans states representing 40% of the U.S. population, with Medicare Part D ramp and further coverage expansion expected in 2025.

• Board leadership transition: Keith Leonard appointed chair, Patrick Heron remains as independent director.

• Co-promotion agreement with Kowa Pharmaceuticals to expand ZORYVE reach in primary care and pediatrics, with material contributions expected in 2025.

Financial highlights

• Net product revenue for Q3 2024 was $44.8 million, up from $8.1 million in Q3 2023 and $30.9 million in Q2 2024.

• R&D expenses were $19.5 million, down 26% year-over-year; SG&A expenses were $58.8 million, up from $47.6 million last year.

• Net loss narrowed to $41.5 million ($0.33/share) from $44.8 million ($0.73/share) in Q3 2023.

• Cash, cash equivalents, and marketable securities totaled $331.2 million as of September 30, 2024.

• $100 million of long-term debt was prepaid in October 2024, reducing principal to $100 million and extending maturity to August 2029.

Outlook and guidance

• Sustained revenue growth expected into Q4 2024 and 2025, supported by new indications, expanded coverage, and prescriber base expansion.

• Anticipates further Medicaid and Medicare coverage wins, expansion into pediatric and primary care, and FDA approval of ZORYVE foam for scalp and body psoriasis in 2025.

• No anticipated need for equity financing; break-even expected in 2026.

• Data from ARQ-255 Phase 1b study for alopecia areata expected in 1H 2025; IND for ARQ-234 planned for 2025.